Andy Weymann
Directeur Général chez Gelmetix Ltd.
Profil
Andy Weymann is currently the Chief Executive Officer & Director at Gelmetix Ltd.
He is also a Director at VirtaMed AG and Speratum Biopharma, Inc. Mr. Weymann has a graduate degree from the University of Zurich and an MBA from the University of Rochester Simon Business School.
Postes actifs de Andy Weymann
| Sociétés | Poste | Début |
|---|---|---|
VirtaMed AG
 VirtaMed AG Personnel ServicesCommercial Services VirtaMed AG develops and produces surgical simulators for medical training. The company was founded by G?bor Sz?kely, Stefan Tuchschmid, Raimundo Sierra and Daniel Bachofen on 2nd October 2007 and is headquartered in Schlieren, Switzerland. | Directeur/Membre du Conseil | 01/06/2021 |
Gelmetix Ltd.
 Gelmetix Ltd. Miscellaneous Commercial ServicesCommercial Services Gelmetix Ltd. offers a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. The firm develops a hydrogel to relieve back pain by enabling cells in the spinal disc to get back to normal functioning, which can be injected into the disc by a healthcare professional and replaces the need for invasive back surgery. The company was founded by Tony Freemont and Brian Saunders in 2012 and is headquartered in Cheshire, the United Kingdom. | Directeur Général | - |
Speratum Biopharma, Inc.
 Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Formation de Andy Weymann
| University of Zurich | Graduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
VirtaMed AG
VirtaMed AG Personnel ServicesCommercial Services VirtaMed AG develops and produces surgical simulators for medical training. The company was founded by G?bor Sz?kely, Stefan Tuchschmid, Raimundo Sierra and Daniel Bachofen on 2nd October 2007 and is headquartered in Schlieren, Switzerland. | Commercial Services |
Gelmetix Ltd.
Gelmetix Ltd. Miscellaneous Commercial ServicesCommercial Services Gelmetix Ltd. offers a non-surgical procedure for the treatment of chronic lower back pain caused by degenerative disc disease. The firm develops a hydrogel to relieve back pain by enabling cells in the spinal disc to get back to normal functioning, which can be injected into the disc by a healthcare professional and replaces the need for invasive back surgery. The company was founded by Tony Freemont and Brian Saunders in 2012 and is headquartered in Cheshire, the United Kingdom. | Commercial Services |
Speratum Biopharma, Inc.
Speratum Biopharma, Inc. BiotechnologyHealth Technology Speratum Biopharma, Inc. is a pre-clinical stage biotechnology company based in Dover, DE. Speratum is focused on the research and development of targeted molecular therapeutics for the treatment of cancer. The company's primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of mir-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids. Speratum's platforms for drug delivery and oligonucleotide administration have broad application potential, and have been out-licensed for multiple therapeutic and research modalities. The company was founded by Christian Marín-Müller, who has been the CEO since incorporation. | Health Technology |